Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

p=0.012 for per protocol populations). While in this exploratory study this endpoint was identified as a secondary end point, FDA currently requires the absolute change (rather than percent change) in the number of inflammatory lesions as one of the co-primary endpoints, along with Treatment Success, for demonstrating efficacy in a Phase III trial in rosacea.

"Based on these encouraging results, we have selected once-daily Omiganan 2.5% for further study in rosacea, which is a critical step towards potential commercialization, either directly or in collaboration with a partner," commented Robert J. Bitterman, President and CEO of Cutanea.

About Rosacea

Rosacea is a chronic dermatologic disorder with no current cure and a poorly understood etiology that afflicts an estimated 14 million Americans. Symptoms primarily manifest on the facial skin and include facial flushing, central facial inflammatory lesions, and facial erythema. According to surveys conducted by the National Rosacea Society (NRS), nearly 70% of rosacea patients said the disorder had lowered their self-confidence and self-esteem; 41% reported it had caused them to avoid public contact or cancel social engagements; and nearly 30% claimed to have missed work due to rosacea. Of these rosacea patients surveyed by the NRS that sought medical treatment, over 70 percent reported an improvement in their emotional and social well-being.

Typical onset of rosacea occurs between 30 and 50 years of age and is more prevalent in women than men. Clearing up the initial outbreak is only the beginning, as rosacea is characterized by periods of relapses and remissions. Relapse episodes can be spurred by sun exposure, stress, hot or cold weather, alcohol, spicy foods, exercise, and certain skin care products and medications.

Absent a cure for rosacea, treatment is aimed at alleviating the disorder's symptoms. Topical or oral medications are generally prescribed for mild to moderate papulopus
'/>"/>

SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, has appointed ... and Managed Markets. Ms. Bauzon has a ... expanding payer coverage for laboratory services companies. She has ... with PerkinElmer, Inc., where she held the position of ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
(Date:8/21/2014)... CHARLOTTE, N.C. , Aug. 21, 2014 /PRNewswire-iReach/ ... Home Medical Equipment, Inc. for the third straight ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ... Yelp, Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Kendle (Nasdaq: KNDL ), a leading, global ... of a planned succession Senior Vice President and COO Stephen ... Chairman and CEO Candace Kendle, PharmD, will continue to serve ... COO from Dr. Cutler will be Jamie Macdonald, who brings ...
... 14, 2011 Zoledronic acid (sold by Novartis as ... Tumor Metastasis, and Paget,s Disease with sales of $2 ... such as post-dose syndrome and osteonecrosis of the jaw. ... the administration of Zoledronic acid in combination with another ...
Cached Medicine Technology:Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 2Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 3Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 4ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination 2
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
(Date:8/21/2014)... 2014 The W. Montague Cobb/ ... a national voice in the elimination of health ... during the 112th National Medical Association’s (NMA) Annual ... , John Ruffin, Ph.D, former Director of the ... whose life-long career and innovations have had a ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... The report "Industrial Flue Gas ... System (FGD, DeNOx, Particulate Control, Mercury Control) by ... & Others) - Global Trends & Forecasts to ... gas treatment systems & services market with analysis ... terms of value. The industrial flue gas treatment ...
Breaking Medicine News(10 mins):Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... of Vermont will elevate the state to being the second ... health-care insurance// , which will cover nearly 96 percent of ... definitely relief for the 46 million Americans who are not ... and costs of insurance premium showing an upward trend, this ...
... getting dirtier despite promises, claimed patients in a survey despite ... ,The annual NHS patients survey has found high levels of ... questions were asked of the 80,000 people who took part ... ward ha been ‘very clean’ as compared to 56% in ...
... Scotland's health minister Andy Kerr said that the NHS staff ... latest statistics on NHS waiting times// as the "best ever". ... had reduced from 12 to 6 months. ,Reports ... number of outpatients and inpatient day cases with an 18-week ...
... cases of diarrhoea in Ranchi, the Jharkhand Health department ... with the disease. // ,'We have equipped ... free-of-cost treatment to patients,' Health and Family Welfare's joint ... patients to avail free treatment at the hospital instead ...
... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
... by the Indian Medical Association, the junior doctors of ... colleges today struck work launching a one-day strike. ... and government dental hospitals were 'totally shut down', emergency ... Assoication, BMC told PTI., ,'We will watch the ...
Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
For the quantitative determination of total cholesterol in serum....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
... The ACS:180 SE is ... ACS:180 PLUS, consisting of important ... further simplify routine operation and ... represents the "Next Generation" ACS:180. ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
Medicine Products: